Sylvia Health was one of 17 research-based startups selected for BioInnovation Institute's Venture Programme, receiving a €560,000 convertible loan as part of BII's €9.52 million deployment across the cohort - the round is listed as undisclosed amount. The article does not disclose Sylvia Health-specific metrics such as clients, revenue, pipeline or employee count, nor a company-specific use of funds or milestone designation, describing only program-level support to turn research into commercially viable businesses including access to BII's Copenhagen lab infrastructure, network of entrepreneurs, experts and investors, and business, scientific and team development including fundraising preparation. The investor is BioInnovation Institute, which has supported 140+ companies to date and, following an additional €736 million from the Novo Nordisk Foundation, plans to expand from backing ~20 to 30 startups annually and scale its activities across Europe.